Patents by Inventor Kathleen W. Scotto

Kathleen W. Scotto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • E2F as a target of hormone refractory prostate cancer
    Patent number: 9314497
    Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: April 19, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Joseph R. Bertino, Debabrata Banerjee, Tamara Minko, Olga B. Garbuzenko, Xiaoqi Xie, John E. Kerrigan, Emine E. Abali, Kathleen W. Scotto
  • E2F AS A TARGET OF HORMONE REFRACTORY PROSTATE CANCER
    Publication number: 20150202248
    Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.
    Type: Application
    Filed: September 2, 2014
    Publication date: July 23, 2015
    Inventors: Joseph R. Bertino, Debabrata Banerjee, Tamara Minko, Olga B. Garbuzenko, Xiaoqi Xie, John E. Kerrigan, Emine E. Abali, Kathleen W. Scotto
  • E2F as a target of hormone refractory prostate cancer
    Patent number: 8822421
    Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: September 2, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Joseph R. Bertino, Debabrata Banerjee, Tamara Minko, Olga B. Garbuzenko, Xiaoqi Xie, John E. Kerrigan, Emine E. Abali, Kathleen W. Scotto
  • E2F AS A TARGET OF HORMONE REFRACTORY PROSTATE CANCER
    Publication number: 20120093919
    Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.
    Type: Application
    Filed: October 14, 2011
    Publication date: April 19, 2012
    Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Joseph R. Bertino, Debabrata Banerjee, Tamara Minko, Olga B. Garbuzenko, Xiaoqi Xie, John E. Kerrigan, Emine E. Abali, Kathleen W. Scotto
  • COMBINATION THERAPY TO IMPROVE DRUG EFFICIENCY
    Publication number: 20120052005
    Abstract: Compositions and methods for increasing drug bioavailability and/or preventing multi-drug resistance through inhibition of ABCG2 by xanthine compounds are disclosed.
    Type: Application
    Filed: August 22, 2011
    Publication date: March 1, 2012
    Applicant: University of Medicine and Dentistry of New Jersey
    Inventors: Rui Ding, Jia Shi, Kathleen W. Scotto
  • Use of flavonoids to treat multidrug resistant cancer cells
    Patent number: 5336685
    Abstract: A method of inhibiting the growth of multidrug resistant cancer cells which comprises contacting multidrug resistant cancer cells with an effective amount of a flavonoid compound. Also, a composition for inhibiting the growth of multidrug resistant cancer cells which comprises a physiologically acceptable carrier and an amount of a flavonoid compound.
    Type: Grant
    Filed: April 12, 1993
    Date of Patent: August 9, 1994
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Hans J. Prochaska, Kathleen W. Scotto